<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Among the secretory phospholipase A2s (sPLA2), sPLA2 group X (PLA2GX) has the most potent hydrolyzing activity toward <z:chebi fb="0" ids="49183">phosphatidylcholine</z:chebi>, and has recently been shown to be implicated in <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C1290884" disease_type="Disease or Syndrome" abbrv="">inflammatory diseases</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of the present study was to investigate PLA2GX expression in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) and its correlation with patient clinicopathological features </plain></SENT>
<SENT sid="2" pm="."><plain>The present study comprises a series of 158 patients who underwent surgical resection for primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>PLA2GX expression in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> tissues was examined by immunohistochemistry and compared with patient clinicopathological findings and survival </plain></SENT>
<SENT sid="4" pm="."><plain>A total of 64% of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> expressed PLA2GX at high levels </plain></SENT>
<SENT sid="5" pm="."><plain>Statistical analysis revealed that PLA2GX expression was inversely correlated with hematogenous <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> (P=0.005) </plain></SENT>
<SENT sid="6" pm="."><plain>In the subgroup analysis, left-sided <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> with high PLA2GX expression showed an inverse correlation with lymph node <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> (P=0.018) and hematogenous <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> (P=0.017) </plain></SENT>
<SENT sid="7" pm="."><plain>Patients with high PLA2GX expression tended to have a longer disease-specific survival compared with those with low PLA2GX expression in left-sided, but not right-sided, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> (P=0.08) </plain></SENT>
<SENT sid="8" pm="."><plain>In light of the present results, we suggest that PLA2GX has an inhibitory effect on the progression of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
</text></document>